• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair.

作者信息

Peng Xin, Wang Yingying, Zhang Shaolu, Tao Zhennan, Dai Yuxiang, Claret Francois X, Elkabets Moshe, Lin Hou-Wen, Chen Zhe-Sheng, Kong Dexin

机构信息

Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.

Key Laboratory of Immune Microenvironment and Diseases (Ministry of Education), Tianjin Medical University, Tianjin, 300070, China.

出版信息

Signal Transduct Target Ther. 2023 Mar 22;8(1):119. doi: 10.1038/s41392-023-01324-8.

DOI:10.1038/s41392-023-01324-8
PMID:36944633
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10030553/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8dc/10030553/c6d6dbcd4b3d/41392_2023_1324_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8dc/10030553/c6d6dbcd4b3d/41392_2023_1324_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8dc/10030553/c6d6dbcd4b3d/41392_2023_1324_Fig1_HTML.jpg

相似文献

1
Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair.海星皂素B通过抑制同源定向修复使胶质母细胞瘤对聚（ADP - 核糖）聚合酶抑制剂敏感。
Signal Transduct Target Ther. 2023 Mar 22;8(1):119. doi: 10.1038/s41392-023-01324-8.
2
A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.聚（ADP-核糖）聚合酶（PARP）抑制剂及合成方法综述
Curr Med Chem. 2021;28(8):1565-1584. doi: 10.2174/0929867327666200312113011.
3
Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.初治卵巢癌中鲁卡帕尼维持治疗：预测对聚（ADP-核糖）聚合酶抑制剂反应的长期挑战
J Clin Oncol. 2023 Feb 1;41(4):935-936. doi: 10.1200/JCO.22.01585. Epub 2022 Oct 6.
4
Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary?聚（ADP）-核糖聚合酶抑制剂与阿比特龙联合用于去势抵抗性前列腺癌：是否需要进行生物标志物检测？
J Clin Oncol. 2023 Jun 20;41(18):3291-3294. doi: 10.1200/JCO.23.00270. Epub 2023 Mar 23.
5
Association of BRCA mutation status with the efficacy of poly (ADP-ribose) polymerase inhibitors in cancer: A systematic review and meta-analysis.BRCA突变状态与聚（ADP-核糖）聚合酶抑制剂在癌症治疗中的疗效的关联：一项系统评价和荟萃分析。
Asian J Surg. 2023 Dec;46(12):5473-5474. doi: 10.1016/j.asjsur.2023.07.118. Epub 2023 Aug 2.
6
In vitro antitumor activity of stellettin B, a triterpene from marine sponge Jaspis stellifera, on human glioblastoma cancer SF295 cells.来自海洋海绵星状扁玉螺的三萜类化合物——星骨素B对人胶质母细胞瘤SF295细胞的体外抗肿瘤活性。
Mar Drugs. 2014 Jul 15;12(7):4200-13. doi: 10.3390/md12074200.
7
Maintenance therapy with a poly (ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: updated individual patient data and trial-level meta-analysis.聚（ADP-核糖）聚合酶抑制剂用于新诊断的晚期上皮性卵巢癌患者的维持治疗：更新的个体患者数据及试验水平的荟萃分析
ESMO Open. 2022 Dec;7(6):100632. doi: 10.1016/j.esmoop.2022.100632. Epub 2022 Nov 7.
8
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.组蛋白去乙酰化酶（HDAC）与聚（ADP - 核糖）聚合酶（PARP）联合靶向治疗胶质母细胞瘤的疗效增强。
Mol Oncol. 2016 May;10(5):751-63. doi: 10.1016/j.molonc.2015.12.014. Epub 2016 Jan 8.
9
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.Rad51降解：在胶质母细胞瘤溶瘤病毒-聚（ADP-核糖）聚合酶抑制剂联合治疗中的作用
J Natl Cancer Inst. 2017 Mar 1;109(3):1-13. doi: 10.1093/jnci/djw229.
10
Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.聚（ADP - 核糖）聚合酶抑制剂的同源重组修复或同源重组缺陷检测：当前观点
Eur J Cancer. 2023 Jan;179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub 2022 Nov 2.

引用本文的文献

1
Glioblastoma at the crossroads: current understanding and future therapeutic horizons.处于十字路口的胶质母细胞瘤：当前的认识与未来的治疗前景
Signal Transduct Target Ther. 2025 Jul 9;10(1):213. doi: 10.1038/s41392-025-02299-4.
2
Antitumor effect of BC12-3 on multiple myeloma via proteasome inhibition.BC12-3通过抑制蛋白酶体对多发性骨髓瘤的抗肿瘤作用。
Med Oncol. 2025 Jun 3;42(7):235. doi: 10.1007/s12032-025-02804-3.
3
Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for Glioblastoma.聚腺苷二磷酸核糖聚合酶（PARP）和溴结构域和 extra-terminal 结构域（BET）的顺序抑制作为胶质母细胞瘤的合理治疗策略。

本文引用的文献

1
Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.胶质母细胞瘤通过表观遗传免疫编辑获得髓系相关转录程序，从而引发免疫逃逸。
Cell. 2021 Apr 29;184(9):2454-2470.e26. doi: 10.1016/j.cell.2021.03.023. Epub 2021 Apr 14.
2
Total Synthesis of Stelletins through an Unconventional Annulation Strategy.通过非常规环合策略的 Stelletins 全合成。
Acc Chem Res. 2021 Apr 6;54(7):1597-1609. doi: 10.1021/acs.accounts.0c00840. Epub 2021 Feb 26.
3
Natural products in drug discovery: advances and opportunities.
Adv Sci (Weinh). 2024 Aug;11(30):e2307747. doi: 10.1002/advs.202307747. Epub 2024 Jun 19.
天然产物在药物发现中的应用：进展与机遇。
Nat Rev Drug Discov. 2021 Mar;20(3):200-216. doi: 10.1038/s41573-020-00114-z. Epub 2021 Jan 28.
4
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.PI3K 抑制会损害 BRCA1/2 的表达，并使 BRCA 功能正常的三阴性乳腺癌对 PARP 抑制敏感。
Cancer Discov. 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22.
5
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.同步放化疗联合辅助替莫唑胺与单纯放疗对胶质母细胞瘤生存影响的随机III期研究：EORTC-NCIC试验的5年分析
Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.